The accurate definition and staging of chronic kidney disease (CKD) is one of the major
achievements of modern nephrology. Intensive research is now being undertaken to unravel …

Hemolytic uremic syndrome (HUS) is defined by the triad of mechanical hemolytic anemia,
thrombocytopenia and renal impairment. Atypical HUS (aHUS) defines non Shiga-toxin …

Antiangiogenesis agents that target the VEGF/VEGF receptor pathway have become an
important part of standard therapy in multiple cancer indications. With expanded clinical …

Molecularly targeted cancer therapies, such as small-molecule kinase inhibitors and
monoclonal antibodies, constitute a rapidly growing and an important part of the oncology …

Proteinuria is a dose-related side-effect occurring after inhibition of vascular endothelial
growth factor (VEGF) signalling and may reflect severe glomerular damage. The inhibition of …

The use of anti-angiogenic agents as part of the therapeutic armamentarium for advanced
stage solid tumors has become the standard of care in several instances, particularly for …

Diabetic kidney disease remains a major microvascular complication of diabetes and the
most common cause of chronic kidney failure requiring dialysis in the United States. Medical …

Abstract Treatment with the chemotherapeutic agent bevacizumab, a humanized mAb that
neutralizes vascular endothelial growth factor, can lead to proteinuria and renal damage …

Expanded clinical experience with patients taking antiangiogenic compounds has come with
increasing recognition of the renal adverse effects. Because renal histology is rarely sought …

To assess the literature on preclinical and clinical efficacy and safety data of pharmacologic
groups proposed in the treatment of endometriosis, we performed a systematic review of …